Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Clinical trial NCT07624513 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07624513
- Sponsor
- Dana-Farber Cancer Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-08
- Primary completion
- 2033-10-01
- Enrollment
- 720
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.